Citations

Showing 10 of 108162 citations.

Right Ventricular Pressure–Volume Analysis Before and After Transcatheter Leaflet Approximation for Severe Mitral Regurgitation
Sarraf, Mohammad , Brener, Michael I. , Burkhoff, Daniel

Mayo Clinic

JAMA Cardiology | February 8, 2021 | Volume: 6 | Issue: 2 | Pages: e207209

10.1001/jamacardio.2020.7209 | PMID 33555300 Get It

Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma
Botrus, Gehan , Kosirorek, Heidi, Kusne, Yael , Usón, Pedro Luiz Serrano , Ahn, Daniel H. , Drusbosky, Leylah , Dada, Hiba I., Surapaneni, Phani Keerthi, Starr, Jason S. , Ritter, Ashton, McMillan, Jessica , Wylie, Natasha , Mody, Kabir , Bekaii‐Saab, Tanios , Sonbol, Mohamad Bassam , Uson Junior, Pedro Luiz Serrano, Uson, Pedro L S , Bekaii-Saab, Tanios S , Borad, Mitesh J. , Kasi, Pashtoon Murtaza

Mayo Clinic

The Oncologist | February 8, 2021 | Volume: 26 | Issue: 7 | Pages: 569-578

10.1002/onco.13717 | PMID 33555095 Get It

Abstract Purpose Recent advances in molecular diagnostic technologies allow for the evaluation of solid tumor malignancies through noninvasive blood sampling, including circulating tumor DNA profiling (ctDNA). Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, often because of late presentation of disease. Diagnosis is often made using endoscopic ultrasound or endoscopic retrograde cholangiopancreatography, which often does not yield enough tissue for next-generation sequencing. With this study, we sought to characterize the ctDNA genomic alteration landscape in patients with advanced PDAC with a focus on actionable findings. Materials and Methods From December 2014 through October 2019, 357 samples collected from 282 patients with PDAC at Mayo Clinic underwent ctDNA testing using a clinically available assay. The majority of samples were tested using the 73-gene panel which includes somatic genomic targets, including complete or critical exon coverage in 30 and 40 genes, respectively, and in some, amplifications, fusions, and indels. Clinical data and outcome variables were available for 165 patients; with 104 patients at initial presentation. Results All patients included in this study had locally advanced or metastatic PDAC. Samples having at least one alteration, when variants of unknown significance (VUS) were excluded, numbered 266 (75%). After excluding VUS, therapeutically relevant alterations were observed in 170 (48%) of the total 357 cohort, including KRAS (G12C), EGFR, ATM, MYC, BRCA, PIK3CA, and BRAF mutations. KRAS, SMAD, CCND2, or TP53 alterations were seen in higher frequency in patients with advanced disease. Conclusion Our study is the largest cohort to date that demonstrates the feasibility of ctDNA testing in PDAC. We provide a benchmark landscape upon which the field can continue to grow. Future applications may include use of ctDNA to guide treatment and serial monitoring of ctDNA during disease course to identify novel therapeutic targets for improved prognosis. Implications for Practice Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis often due to late presentation of disease. Biopsy tissue sampling is invasive and samples are often inadequate, requiring repeated invasive procedures and delays in treatment. Noninvasive methods to identify PDAC early in its course may improve prognosis in PDAC. Using ctDNA, targetable genes can be identified and used for treatment.
APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable
Vile, Richard G. , Melcher, Alan , Pandha, Hardev , Harrington, Kevin J. , Pulido, José S. , Melcher, Alan A , Harrington, Kevin

Mayo Clinic

Clinical Cancer Research | February 8, 2021 | Volume: 27 | Issue: 12 | Pages: 3280-3290

10.1158/1078-0432.ccr-20-1888 | PMID 33558423 Get It

AbstractThe apolipoprotein B mRNA editing enzyme catalytic polypeptide (APOBEC) family protects against infection by degrading incoming viral genomes through cytosine deamination. Here, we review how the potential to unleash these potent DNA mutagens comes at a price as APOBEC DNA mutagenesis can contribute to development of multiple types of cancer. In addition, because viral infection induces its expression, APOBEC is seen as the enemy of oncolytic virotherapy through mutation of the viral genome and by generating virotherapy-resistant tumors. Therefore, overall APOBEC in cancer has received very poor press. However, we also speculate how there may be silver linings to the storm clouds (kataegis) associated with APOBEC activity. Thus, although mutagenic genomic chaos promotes emergence of ever more aggressive subclones, it also provides significant opportunity for cytotoxic and immune therapies. In particular, the superpower of cancer immunotherapy derives in part from mutation, wherein generation of tumor neoantigens—neoantigenesis—exposes tumor cells to functional T-cell repertoires, and susceptibility to immune checkpoint blockade. Moreover, APOBECs may be able to induce suprathreshold levels of cellular mutation leading to mitotic catastrophe and direct tumor cell killing. Finally, we discuss the possibility that linking predictable APOBEC-induced mutation with escape from specific frontline therapies could identify mutated molecules/pathways that can be targeted with small molecules and/or immunotherapies in a Trap and Ambush strategy. Together, these considerations lead to the counterintuitive hypothesis that, instead of attempting to expunge and excoriate APOBEC activity in cancer therapy, it might be exploited—and even, counterintuitively, encouraged.
Reducing Broad-Spectrum Antimicrobial Use in Extracorporeal Membrane Oxygenation: Reduce AMMO Study
Shah, Aditya , Sampathkumar, Priya , Bohman, J. Kyle , Lahr, Brian D. , Dhungana, Prabij, Vashistha, Kirtivardhan , O'Horo, John C, Bohman, John K , Stevens, Ryan W. , O’Horo, John C.

Mayo Clinic

Clinical Infectious Diseases | February 8, 2021 | Volume: 73 | Issue: 4 | Pages: e988-e996

10.1093/cid/ciab118 | PMID 33575744 Get It

Abstract Background The use of extracorporeal membrane oxygenation (ECMO) in critically ill adults is increasing. There are currently no guidelines for antimicrobial prophylaxis. We analyzed 7 years of prophylactic antimicrobial use across 3 time series for patients on ECMO at our institution in the development, improvement, and streamlining of our ECMO antimicrobial prophylaxis protocol. Methods In this quasi-experimental interrupted time series analysis, we evaluated the impact of an initial ECMO antimicrobial prophylaxis protocol, implemented in 2014, on antimicrobial use and National Healthcare Safety Network–reportable infection rates. Then, following a revision and streamlining of the protocol in November 2018, we reevaluated the same metrics. Results Our study population included 338 intensive care unit patients who received ECMO between July 2011 and November 2019. After implementation of the first version of the protocol, we did not observe significant changes in antimicrobial use or infection rates in these patients; however, following revision and streamlining of the protocol, we demonstrated a significant reduction in broad-spectrum antimicrobial use for prophylaxis in patients on ECMO without any evidence of a compensatory increase in infection rates. Conclusions Our final protocol significantly reduces broad-spectrum antimicrobial use for prophylaxis in patients on ECMO. We propose a standard antimicrobial prophylaxis regimen for patients on ECMO based on current evidence and our experience. Summary: There are no guidelines for antimicrobial prophylaxis in patients on extracorporeal membrane oxygenation (ECMO). A rational approach employing concepts of antimicrobial stewardship can drive logical antimicrobial selection for prophylaxis in patients on ECMO without adversely impacting outcomes.
Intraarterial Degradation of Calcium Hydroxylapatite Using Sodium Thiosulfate – An In Vitro and Cadaveric Study
Yankova, Mariya , Pavicic, Tatjana , Frank, Konstantin , Schenck, Thilo L., Beleznay, Kate, Gavril, Diana L., Voropai, Daria , Robinson, Deanne Mraz, Velthuis, Peter J. , Frank, Konstantin , Green, Jeremy B. , Cotofana, Sebastian

Mayo Clinic

Aesthetic Surgery Journal | February 8, 2021 | Volume: 41 | Issue: 5 | Pages: NP226-NP236

10.1093/asj/sjaa350 | PMID 33544840 Get It

Abstract Background The most severe complications following soft tissue filler injections result from the intraarterial administration of the filler product. Although hyaluronic acid–based filler can be trans-arterially dissolved with hyaluronidase, no information is available on calcium hydroxylapatite (CaHA)-based fillers. Objective The authors sought to test whether CaHA-based fillers can be trans-arterially dissolved by sodium thiosulfate (STS) when evaluated in cadaveric and in vitro models. Methods Human cadaveric facial arterial segments were each filled with 0.2 cc of commercially available CaHA product and submerged for 24 hours in 4 different STS-containing solutions: 10 cc STS (300 mg/cc) (pure, 1:1 dilution, 1:2 dilution), 0.9% saline and 10 cc STS (300 mg/cc), and 300 IU (bovine) hyaluronidase in a 1:1 ratio. Results Intraarterial CaHA was detected in human facial artery segments after 24 hours independent of the STS concentration employed. Submerging the arterial segments in STS (300 mg/cc) and 300 IU (bovine) hyaluronidase (1:1 ratio) also did not dissolve the intraarterial CaHA product. Gray scale analyses did show, however, that increasing concentrations of STS resulted in increased disintegration of CaHA in an in vitro experimental setting. Conclusions The results of this study indicate that STS is limited in its potential to dissolve intraarterial CaHA of cadaveric human facial arteries, despite the fact that it appears effective when in direct contact with the CaHA. Adverse events caused by intraarterial administration of CaHA-based fillers still lack a suitable antidote.
Acute isolated trigeminal neuropathy following calcium hydroxylapatite‐based soft tissue filler injection: A case report
Мингазова, Л. Р. , Karpova, E.I. , Murakov, S.V. , Orlova, Olga , Голубев, В Л , Cotofana, Sebastian , Mingazova, Leniza , Cotofana, Sebastian

Mayo Clinic

Journal of Cosmetic Dermatology | February 8, 2021 | Volume: 20 | Issue: 5 | Pages: 1505-1511

10.1111/jocd.13959 | PMID 33547864 Get It

Abstract Background Soft tissue filler injections are frequently performed with a relatively low number of severe adverse events reported. While venous complications have been described, the majority of adverse events are generally associated with the arterial vascular system. Intra‐arterial product application can present with pain, skin discoloration, and potential tissue loss and/or injection related visual compromise. Aim We present the clinical case and the consecutive symptomology of a 39‐year‐old woman injected with calcium hydroxylapatite at the zygomatic arch with five perpendicular needle (27G 12mm) supraperiosteal bolus injections of 0.2 cc per site. Methods Immediately after the injections, weakness, nausea, vomiting, and loss of consciousness occurred. Additionally, left‐sided loss of sensation of her face, scalp, oral, and nasal mucosa occurred, with absence of left corneal reflex and ipsi‐lateral ear congestion. Subsequently, left‐sided masseteric atrophy and dysphagia occurred. Results One year after the injection procedure the sensory loss of her facial skin and scalp persisted, while the other symptoms improved. Medications involved in the symptomatic (not causal) partial recovery process were Dexamethasone, Vitamin B complex, Vinpocetine, Pentoxifyllin, and Thioctic acid. Conclusion The symptoms presented and the time‐related relationship to the injection procedure increases the likeliness of an association between the administration of the calcium hydroxylapatite product and a lesion of the trigeminal ganglion. The resulting symptoms can altogether be related to the functions of the ganglion. The connecting pathway between the injection site and the ganglion can be explained by the arterial vascular pathway.
The Mutation Matters: CSF Profiles of GCase , Sphingolipids, α‐Synuclein in PD
Lerche, Stefanie , Schulte, Claudia , Wurster, Isabel , Machetanz, Gerrit , Röeben, Benjamin , Deuschle, Christian , Hauser, Ann‐Kathrin , Böhringer, Judith , Waniek, Katharina , Lachmann, Ingolf , Petterson, Xuan-Mai, Chiang, Ruby W., Liepelt‐Scarfone, Inga , Maetzler, Walter , Gasser, Thomas , Hutten, Samantha J. , Mollenhauer, Brit , Sardi, S. Pablo , Berg, Daniela , Brockmann, Kathrin , Petterson, Xuan-Mai T, Schulte, Claudia , Zimmermann, Milan , Krägeloh‐Mann, Ingeborg , Chiang, Ruby, Park, Hye Jung , Wang, Bing , Galasko, Douglas , Scherzer, Clemens R. , Mielke, Michelle M.

Mayo Clinic

Movement Disorders | February 8, 2021 | Volume: 36 | Issue: 5 | Pages: 1216-1228

10.1002/mds.28472 | PMID 33547828 Get It

ABSTRACT Background With pathway‐specific trials in PD associated with variants in the glucocerebrosidase gene (PD GBA ) under way, we need markers that confirm the impact of genetic variants in patient‐derived biofluids in order to allow patient stratification merely based on genetics and that might serve as biochemical read‐out for target engagement. Objective To explore GBA‐pathway‐specific biomarker profiles cross‐sectionally (TUEPAC‐MIGAP, PPMI) and longitudinally (PPMI). Methods We measured enzyme activity of the lysosomal glucocerebrosidase, CSF levels of glucosylceramides (upstream substrate of glucocerebrosidase), CSF levels of ceramides (downstream product of glucocerebrosidase), lactosylceramides, sphingosines, sphingomyelin (by‐products) and CSF levels of total α‐synuclein in PD GBA patients compared to PD GBA_wildtype patients. Results Cross‐sectionally in both cohorts and longitudinally in PPMI: (1) glucocerebrosidase activity was significantly lower in PD GBA compared to PD GBA_wildtype . (2) CSF levels of upstream substrates (glucosylceramides species) were higher in PD GBA compared to PD GBA_wildtype . (3) CSF levels of total α‐synuclein were lower in PD GBA compared to PD GBA_wildtype . All of these findings were most pronounced in PD GBA with severe mutations (PD GBA_severe ). Cross‐sectionally in TUEPAC‐MIGAP and longitudinally in PPMI, CSF levels of downstream‐products (ceramides) were higher in PD GBA_severe . Cross‐sectionally in TUEPAC‐MIGAP by‐products sphinganine and sphingosine‐1‐phosphate and longitudinally in PPMI species of by‐products lactosylceramides and sphingomyelin were higher in PD GBA_severe . Interpretation These findings confirm that GBA mutations have a relevant functional impact on biomarker profiles in patients. Bridging the gap between genetics and biochemical profiles now allows patient stratification for clinical trials merely based on mutation status. Importantly, all findings were most prominent in PD GBA with severe variants. © 2021 International Parkinson and Movement Disorder Society
Bioelectronic Sensor Technology for Detection of Cystic Fibrosis and Hereditary Hemochromatosis Mutations
Bernacki, Susan H. , Farkas, Daniel H., Shi, Wenmei, Chan, Vivian, Liu, Yenbou, Beck, Jeanne C., Bailey, Karen Snow, Pratt, Victoria M. , Monaghan, Kristin G. , Matteson, Karla J., Schaefer, Frederick V., Friez, Michael J., Shrimpton, Antony E., Stenzel, Timothy T. , Chan, Vivian

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 8, 2021 | Volume: 127 | Issue: 12 | Pages: 1565-1572

10.5858/2003-127-1565-bstfdo | PMID 14632577 Get It

Abstract Context. —Bioelectronic sensors, which combine microchip and biological components, are an emerging technology in clinical diagnostic testing. An electronic detection platform using DNA biochip technology (eSensor) is under development for molecular diagnostic applications. Owing to the novelty of these devices, demonstrations of their successful use in practical diagnostic applications are limited. Objective. —To assess the performance of the eSensor bioelectronic method in the validation of 6 Epstein-Barr virus–transformed blood lymphocyte cell lines with clinically important mutations for use as sources of genetic material for positive controls in clinical molecular genetic testing. Two cell lines carry mutations in the CFTR gene (cystic fibrosis), and 4 carry mutations in the HFE gene (hereditary hemochromatosis). Design. —Samples from each cell line were sent for genotype determination to 6 different molecular genetic testing facilities, including the laboratory developing the DNA biochips. In addition to the bioelectronic method, at least 3 different molecular diagnostic methods were used in the analysis of each cell line. Detailed data were collected from the DNA biochip output, and the genetic results were compared with those obtained using the more established methods. Results. —We report the successful use of 2 applications of the bioelectronic platform, one for detection of CFTR mutations and the other for detection of HFE mutations. In all cases, the results obtained with the DNA biochip were in concordance with those reported for the other methods. Electronic signal output from the DNA biochips clearly differentiated between mutated and wild-type alleles. This is the first report of the use of the cystic fibrosis detection platform. Conclusions. —Bioelectronic sensors for the detection of disease-causing mutations performed well when used in a “real-life” situation, in this case, a validation study of positive control blood lymphocyte cell lines with mutations of public health importance. This study illustrates the practical potential of emerging bioelectronic DNA detection technologies for use in current molecular diagnostic applications.
Delayed Gastric Emptying in Prelung Transplant Patients Is Associated With Posttransplant Acute Cellular Rejection Independent of Reflux
Derousseau, Taylor, Chan, Walter W., Cangemi, David, Kaza, Vaidehi, Lo, Wai-Kit, Gavini, Sravanya, Chan, Walter W. , Lo, Wai–Kit , Chan, Walter , Derousseau, Taylor, Chan, Walter W., Cangemi, David, Kaza, Vaidehi, Lo, Wai-Kit, Gavini, Sravanya

Mayo Clinic

Journal of Clinical Gastroenterology | February 8, 2021 | Volume: 56 | Issue: 2 | Pages: e121-e125

10.1097/mcg.0000000000001502 | PMID 33780225 Get It

Goal: The goal of this study was to evaluate the relationship between pretransplant delayed gastric emptying (DGE) and posttransplant acute cellular rejection (ACR) in lung transplant recipients. Background: DGE is very prevalent (23% to 91%) after lung transplantation but pretransplant prevalence has not been well studied. DGE may lead to poor posttransplant outcomes by predisposing to microaspiration. Pretransplant testing for DGE may help identify patients at risk for negative posttransplant outcomes including ACR. Materials and Methods: A retrospective review of a prospectively collected database of consecutive patients undergoing prelung transplant evaluation at a tertiary referral center from 2010 to 2015 was performed. Patients with pretransplant gastric emptying scintigraphy were included in the study. ACR diagnosis was made using International Society for Heart and Lung Transplantation (ISHLT) histologic criteria. Typical gastroparesis symptoms at the time of gastric emptying scintigraphy and pretransplant 24-hour pH impedance monitoring (MII-pH) data was collected. Logistic regression was used for multivariate analysis. Subgroup analyses were performed to account for gastroesophageal reflux (GER). Results: A total of 83 subjects (18 with DGE, 51.8% male, mean age: 53.6 y) met the criteria for inclusion. Patients with DGE were more likely to have typical symptoms of gastroparesis, though 61.1% of DGE patients were asymptomatic. ACR was more prevalent in patients with DGE (33.3% vs. 12.3%, P =0.04). This correlation was independent of GER as measured by MII-pH on subgroup analysis (75% vs. 14.3%, n=0.02). Discussion: Lung transplant recipients with pretransplant DGE have a higher incidence of ACR, independent of GER. Routine pretransplant testing for DGE may help identify patients at greater risk for adverse posttransplant outcomes as the majority of patients with DGE are asymptomatic.